NCT00260962|CompletedPhase 2Results
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · Eli Lilly
interventional
34
1 country
1
Study Start
September 2000
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2006
Actual (reported)Study Completion
September 2006
Actual (reported)The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2000
Date type not reportedThis date has not been verified as actual or estimated.
November 30, 2005
Actual (reported)December 2, 2005
Actual (reported)July 2006
Actual (reported)September 2006
Actual (reported)April 28, 2017
Actual (reported)Body Mass Index (BMI) (kg/m^2)
Body Mass Index (BMI) measured in kg/m\^2 units. Measured at Baseline (week 2) and post-treatment (week 13).
Baseline (week 2) and post-treatment (week 13)
Obsessions
Pretreatment (Week 1) and Posttreatment (Week 13)
Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
Ottawa Hospital
Ottawa, Ontario, K1Y 4E9, Canada
Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008 Oct;165(10):1281-8. doi: 10.1176/appi.ajp.2008.07121900. Epub 2008 Jun 16.
H Bissada
OHRI
34 participants (actual enrollment reported by the registry).
First Submitted
November 30, 2005
First Posted
December 2, 2005
Study Start
September 2000
Date type not reportedThis date has not been verified as actual or estimated.
Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
July 2006
Actual (reported)Study Completion
September 2006
Actual (reported)Last Updated
January 30, 2018
Results First Posted
April 28, 2017
Record last verified: 2018-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: